Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) closed down 2.52% on Monday with about 6.5 million shares traded. The company reported positive results in a clinical trial of type 1 diabetes drug LX4211. The trial found that the drug successfully reduced insulin use and improved glycemic control in patients with poorly controlled diabetes. Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX) shares after opening at $1.79 moved to $1.86 on last trade day and at the end of the day closed at $1.55. Company price to sales ratio in past twelve months was calculated as 361.97 and price to cash ratio as 6.19. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) showed a negative weekly performance of -5.49%.
Oi SA (ADR)(NYSE:OIBR) hereby announces to its shareholders and the market in general that it filed the preliminary prospectus supplement relating to the Offering (as defined below) with the U.S. Securities and Exchange Commission on the date hereof. The Offering may initially consist of 1,917,028,657 common shares and 3,834,057,315 preferred shares, totaling 5,751,085,972 shares, including shares in the form of American Depositary Shares, represented by American Depositary Receipts (the “Offering”). Oi SA (ADR)(NYSE:OIBR) shares fell -7.35% in last trading session and ended the day on $1.26.Oi SA (ADR)(NYSE:OIBR) yearly performance is -47.72%.
Exelixis, Inc. (NASDAQ:EXEL) slipped -5.34% against no significant news. Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications. Exelixis, Inc. (NASDAQ:EXEL) shares moved down -1.48% in last trading session and was closed at $3.32, while trading in range of $3.23 – 3.47. Exelixis, Inc. (NASDAQ:EXEL) year to date (YTD) performance is -45.84%.
American Eagle Outfitters (NYSE:AEO)‘s stock had its “neutral” rating restated by analysts at Buckingham Research in a research report issued to clients and investors on Wednesday, AnalystRatings.Net reports. They currently have a $12.00 target price on the stock. Buckingham Research’s target price indicates a potential upside of 5.45% from the company’s current price. American Eagle Outfitters (NYSE:AEO) weekly performance is -6.25%. On last trading day company shares ended up $10.95. American Eagle Outfitters (NYSE:AEO) distance from 50-day simple moving average (SMA50) is -16.44%. Analysts mean target price for the company is $14.28.